loading
前日終値:
$8.25
開ける:
$8.18
24時間の取引高:
305.64K
Relative Volume:
0.79
時価総額:
$442.94M
収益:
当期純損益:
$-161.15M
株価収益率:
-2.1454
EPS:
-3.7149
ネットキャッシュフロー:
$-138.61M
1週間 パフォーマンス:
-0.38%
1か月 パフォーマンス:
-23.80%
6か月 パフォーマンス:
-73.22%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
Value
$0.00
$0.00
1週間の範囲:
Value
$7.84
$8.58
52週間の値動き範囲:
Value
$7.46
$40.43

Maplight Therapeutics Inc Stock (MPLT) Company Profile

Name
名前
Maplight Therapeutics Inc
Name
セクター
Healthcare (1052)
Name
電話
650-839-4360
Name
住所
800 CHESAPEAKE DRIVE, REDWOOD CITY
Name
職員
133
Name
Twitter
Name
次回の収益日
2026-12-03
Name
最新のSEC提出書
Name
MPLT's Discussions on Twitter

Compare MPLT vs VRTX, REGN, MRNA, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
MPLT icon
MPLT
Maplight Therapeutics Inc
7.97 442.94M 0 -161.15M -138.61M -3.7149
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
523.93 132.80B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
805.02 82.88B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
200.10 79.89B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
873.71 54.94B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
377.63 42.72B 5.76B 514.49M 1.10B 4.4813

Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-06 開始されました Guggenheim Neutral
2026-08-10 ダウングレード UBS Buy → Neutral
2026-07-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2026-07-21 開始されました BMO Capital Markets Outperform
2026-06-25 開始されました Raymond James Strong Buy
2026-05-27 開始されました UBS Buy
2026-05-21 開始されました Craig Hallum Buy
2026-05-04 開始されました H.C. Wainwright Buy
2026-04-08 開始されました Needham Buy
2026-04-07 開始されました TD Cowen Buy
2026-03-19 開始されました Canaccord Genuity Buy
2025-11-21 開始されました Jefferies Buy
2025-11-21 開始されました Leerink Partners Outperform
2025-11-21 開始されました Morgan Stanley Overweight
2025-11-21 開始されました Stifel Buy
すべてを表示

Maplight Therapeutics Inc (MPLT) 最新ニュース

pulisher
Oct 16, 2026

MapLight Therapeutics’ Kreitzer sells $96,024 in common stock By Investing.com - Investing.com South Africa

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics CMO Erin Foff sells $124,068 in stock By Investing.com - Investing.com South Africa

Oct 16, 2026
pulisher
Oct 16, 2026

Form 4 MapLight Therapeutics Inc: James Woodruff Lillie (Chief Scientific Officer) For: 15 October - Investing.com Nigeria

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics CMO Erin Foff sells $124,068 in stock - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics chief scientific officer sells $93,025 in shares - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics general counsel reports $72,881 stock sale - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics CAO sells $82,149 in shares - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics’ Kreitzer sells $96,024 in common stock - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics CAO sells $82,149 in shares By Investing.com - Investing.com UK

Oct 16, 2026
pulisher
Oct 16, 2026

MapLight Therapeutics chief scientific officer sells $93,025 in shares By Investing.com - Investing.com UK

Oct 16, 2026
pulisher
Oct 16, 2026

Form 4 MapLight Therapeutics Inc: Anatol Kreitzer (Chief Discovery Officer) For: 15 October - Investing.com Nigeria

Oct 16, 2026
pulisher
Oct 16, 2026

Form 144 MapLight Therapeutics For: 16 October By Investing.com - Investing.com Nigeria

Oct 16, 2026
pulisher
Oct 16, 2026

Form 144 MapLight Therapeutics For: 16 October By Investing.com - Investing.com India

Oct 16, 2026
pulisher
Oct 16, 2026

Form 144 MapLight Therapeutics For: 16 October By Investing.com - Investing.com UK

Oct 16, 2026
pulisher
Oct 15, 2026

MapLight Therapeutics Officer Christopher Kroeger Files to Sell 73,691 Shares to Cover RSU Tax Withholding - Kalkine Media

Oct 15, 2026
pulisher
Oct 15, 2026

MapLight Therapeutics Officer Lillie James Woodruff to Sell 11,513 Shares for RSU Tax Withholding - Kalkine Media

Oct 15, 2026
pulisher
Oct 15, 2026

MapLight Therapeutics Director Robert Malenka Announces Sale of 14,809 RSU Shares via Rule 144 - Kalkine Media

Oct 15, 2026
pulisher
Sep 27, 2026

Form 4 MapLight Therapeutics Inc For: 26 September By Investing.com - Investing.com Nigeria

Sep 27, 2026
pulisher
Sep 26, 2026

Form 4 MapLight Therapeutics Inc For: 26 September By Investing.com - Investing.com Australia

Sep 26, 2026
pulisher
Sep 16, 2026

MapLight Therapeutics (MPLT) exec to sell shares under preset trading plan - stocktitan.net

Sep 16, 2026
pulisher
Sep 11, 2026

MapLight Therapeutics, Inc. (MPLT) Stock Price Quote Today & Current Price Chart - Capital.com

Sep 11, 2026
pulisher
Sep 09, 2026

MapLight Therapeutics to Participate in Upcoming Investor Conference - The Manila Times

Sep 09, 2026
pulisher
Sep 02, 2026

BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat

Sep 02, 2026
pulisher
Sep 01, 2026

Maplight Therapeutics (NASDAQ:MPLT) Trading Up 5.3%Here's What Happened - MarketBeat

Sep 01, 2026
pulisher
Aug 31, 2026

Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com Canada

Aug 31, 2026
pulisher
Aug 31, 2026

Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com India

Aug 31, 2026
pulisher
Aug 31, 2026

Maplight Therapeutics (NASDAQ:MPLT) Price Target Lowered to $43.00 at Needham & Company LLC - MarketBeat

Aug 31, 2026
pulisher
Aug 29, 2026

Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat

Aug 29, 2026
pulisher
Aug 28, 2026

Nan Fung Group Holdings Ltd Makes New $34.81 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat

Aug 28, 2026
pulisher
Aug 26, 2026

Maplight Therapeutics (NASDAQ:MPLT) Trading Down 4.6%What's Next? - MarketBeat

Aug 26, 2026
pulisher
Aug 25, 2026

Maplight Therapeutics (NASDAQ:MPLT) Trading 7.8% HigherShould You Buy? - MarketBeat

Aug 25, 2026
pulisher
Aug 24, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 24, 2026
pulisher
Aug 21, 2026

Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire

Aug 21, 2026
pulisher
Aug 21, 2026

Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat

Aug 21, 2026
pulisher
Aug 20, 2026

MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research

Aug 20, 2026
pulisher
Aug 20, 2026

MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan

Aug 20, 2026
pulisher
Aug 20, 2026

Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat

Aug 20, 2026
pulisher
Aug 19, 2026

MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - stocktitan.net

Aug 19, 2026
pulisher
Aug 19, 2026

MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan

Aug 19, 2026
pulisher
Aug 19, 2026

MapLight Therapeutics (MPLT) grants CSO new options and RSUs - stocktitan.net

Aug 19, 2026
pulisher
Aug 19, 2026

MapLight Therapeutics (MPLT) lifts GC stake with 31K options - stocktitan.net

Aug 19, 2026
pulisher
Aug 19, 2026

MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet

Aug 19, 2026
pulisher
Aug 18, 2026

Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan

Aug 18, 2026
pulisher
Aug 17, 2026

MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research

Aug 17, 2026
pulisher
Aug 17, 2026

MapLight Therapeutics announces $150M private placement - TipRanks

Aug 17, 2026
pulisher
Aug 17, 2026

Morgan Stanley Maintains MapLight Therapeutics(MPLT.US) With Hold Rating, Maintains Target Price $21 - Moomoo

Aug 17, 2026
pulisher
Aug 15, 2026

Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37 - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20 - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News

Aug 14, 2026

Maplight Therapeutics Inc (MPLT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Maplight Therapeutics Inc (MPLT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Foff Erin Pennock
Chief Medical Officer
Oct 15 '26
Sale
8.08
15,355
124,068
296,906
Kroeger Christopher A.
Chief Executive Officer
Oct 15 '26
Sale
8.08
73,691
595,423
1,195,909
Lillie James Woodruff
Chief Scientific Officer
Oct 15 '26
Sale
8.08
11,513
93,025
198,597
Lillie James Woodruff
Officer
Oct 15 '26
Proposed Sale
7.81
11,513
89,917
0
Kroeger Christopher A.
Officer
Oct 15 '26
Proposed Sale
7.81
73,691
575,527
0
GILLIS JONATHAN
Officer
Oct 15 '26
Proposed Sale
7.81
10,167
79,404
0
Hanson Kristopher
Officer
Oct 15 '26
Proposed Sale
7.81
9,020
70,446
0
Foff Erin Pennock
Officer
Oct 15 '26
Proposed Sale
7.81
15,355
119,922
0
GILLIS JONATHAN
CAO and Interim CFO
Oct 15 '26
Sale
8.08
10,167
82,149
142,315
Anatol Kreitzer
Officer
Oct 15 '26
Proposed Sale
7.81
12,500
97,625
0
$7.85
price down icon 3.09%
$9.75
price up icon 0.72%
$8.03
price down icon 4.18%
$5.85
price down icon 0.17%
WVE WVE
$3.18
price down icon 5.07%
$13.83
price down icon 4.62%
大文字化:     |  ボリューム (24 時間):